Nostra historia

 

 

 
2016

• Statutum in Hangzhou, China

 
2017

• Ab regulatory approbatione ad primum- generationem celeri diagnostica producta pro cura.

 
2018

• Expansum in mercatus internationales cum bio- solutionibus diagnostica.

 
2019

Publice • celeri probatio products ad iumenta launched

 
2021-2022

• Completus R&D Centrum, QA/QC dolor, et GMP- facilitas productionis certificata.

 
2022.3

• Achieved ISO (IX)I certificatione

• Pro Biosafety Level II Laboratorium.

 
2022.4

• R&D incepta programmata diagnostica curarum exoticorum.

•Pioneered primum Cryptosporidium mundi antigenis test habena pro reptilibus.

 
2022.5

• Socius factus Sinarum Consociationis Veterinariae Medical

 
2022.12

• VD notae producta in 40+ terris distributa.

• Secured >60% forum participes in clavis regionum.

 
2023.2

• CHENGDU EVEGEN BIOTECH fundatus CO., LTD ad productionem et logistics confirmandos.

 
2023.6

• Sinis veterinarii medicamentis Societas coniuncta.

 
2023.7

• Ab ISO 14001 et ISO 45001 certificaciones.

• Chengdu subsidiaria acquisita GSP licentia medicamento veterinarii.

 
2023.9

• patentes in Feline Herpesvirus Type I (FHV-1)

• nactus patentes in infectious Anemia Virus Equine

 
2024.10

• Patentes in Leishmania Antibody Test

 
2025.1

• nactus patentes in Leishmania Caninae

 
2025.3

• Patentes in anti-ETEC K99 anticorpus monoclonale nacta